The Health Implication of Enterohaemorrhagic Escherichia coli (EHEC) 0157:H7: A Review on Haemolytic Uraemic Syndrome

Main Article Content

Onengiyeofori Ibama
Edna O. Ibegbulem
Donatus Onwuli
Adline Ben-Chioma

Abstract

Consumption of foods, water, vegetables, fruits, undercooked/ground/raw meat, unpasteurized milk or milk products contaminated with the bacterium strain Escherichia coli 0157:H7 has become a serious public health concern. This strain naturally inhabits the digestive tract of healthy cattle, and is released into the environment through the faeces of the animal. This strain cause haemorrhagic enterocolitis or gastroenteritis, and then haemolytic uraemic syndrome (HUS). HUS is a disorder characterised by haemolytic anaemia, low platelet count and acute kidney failure, and this disorder is a consequence of the production and action of Shiga-like toxin produced mainly by this bacterial strain (accounting for 90 percent of all cases), and occurs mainly in children less than five (5) years of age, but also occurs in the elderly. After infection with this bacterial strain, the disorder begins with intestinal perforation and ulceration leading to bloody diarrhoea, and consequently acute kidney injury, thrombocytopenia and microangiopathic haemolytic anaemia. In conjunction with clinical manifestations, several laboratory investigations (haematological, biochemical and microbiological assays) are implicated in the diagnosis of HUS. There is currently no specific treatment for HUS; however, supportive care (such as treatment of hypertension, fluid and electrolyte imbalance, haemodialysis, blood transfusion, etc) happens to be the only ameliorative measure for this disorder.

Keywords:
Enterocolitis, haemorrhagic, diarrhea, disorder, haemodialysis.

Article Details

How to Cite
Ibama, O., Ibegbulem, E. O., Onwuli, D., & Ben-Chioma, A. (2019). The Health Implication of Enterohaemorrhagic Escherichia coli (EHEC) 0157:H7: A Review on Haemolytic Uraemic Syndrome. Asian Journal of Research in Medical and Pharmaceutical Sciences, 7(4), 1-10. https://doi.org/10.9734/ajrimps/2019/v7i430129
Section
Review Article

References

Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. Journal of Internal Medicine. 2016;281:123–148.

Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/ Natal. Pediatric Nephrology. 1997;11:560-564.

Tozzi AE, Caprioli A, Minelli F. Shiga toxin-producing Escherichia coli infections associated with haemolytic uremic syndrome, Italy, 1988-2000. Emerging Infectious Diseases. 2003;9:106-108.

Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infection And Immunity. 1977;18:775–779.

Riley LW, Remis RS, Helgerson SD. Hemorrhagic colitis associated with a rare Escherichia coli serotype. New England Journal of Medicine. 1983;308:681–685.

Azuonwu O, Abbey SD, Wokem GN, Adegoke. Hemorrhagic colitis and its public health implications: A review. Journal of Pharmacy Research. 2011;4(1):22-23.

Cody SH, Glynn MK, Farrar JA, Cairns L K, Griffin PM, Kobayashi J, Fyfe M, Hoffmann R, King AS, Lewis JH, Swaminathan B, Vugia DJ. An outbreak of E. coli 0157:H7 Infection from unpasteurized commercial apple juice. Annuals of Internal Medicine. 1999;130 :202- 209.

Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. Journal of Internal Medicine. 2017;281:123–148.

Espie E, Grimont F, Mariani-Kurkdjian P. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 shiga toxin-producing Escherichia coli infections in France, 1996– 2006. Pediatric Infectious Disease Journal. 2008;27(7): 595–601.

Canpolat N. Hemolytic uremic syndrome. Turkish Archives of Pediatrics. 2015;50: 73-82

Michino H, Araki K, Minami S. Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. American Journal of Epidemiology. 1999;150:787–796.

Paton AW, Ratcliff RM, Doyle RM. Molecular microbiological investigation of an outbreak of hemolytic-uremic syndrome caused by dry fermented sausage contaminated with Shiga-like toxin-producing Escherichia coli. Journal of Clinical Microbiology. 1996;34:1622–1627.

Rivas M, Miliwebsky E, Chinen I. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathogens Disease. 2006;3:88–96.

Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. New England Journal of Medicine. 2009;361:1676–1687.

Byrne L, Jenkins C, Launders N, Elson R, Adak GK. The epidemiology, microbiology and clinical impact of Shiga toxin-producing Escherichia coli in England, 2009-2012. Epidemiology and Infection. 2015:143:3475–3787.

Tarr PI, Gordon CA, Chandler WL. Shiga-toxin producing Escherichia coli and hemolytic uremic syndrome. Lancet. 2005; 365:1073-1086.

Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatric Nephrology. 2008;23: 1749-1760.

Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerging Infectious Diseases. 2005;11:603–609.

Ludwig K, Sarkim V, Bitzan M. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. Journal of Clinical Microbiology. 2002;40: 1773–1782.

Tilden J, Young W, McNamara AM. A new route of transmission for Escherichia coli: Infection from dry fermented salami. American Journal of Public Health. 1996;. 86:1142–1145.

Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: Molecular events in vascular endothelial injury. International Society of Nephrology. 2009; 75(112):S17–S19.

Jenssen GR, Hovland E, Bjerre A, Bangstad HJ, Nygard K, Vold L. Incidence and etiology of hemolytic-uremic syndrome in children in Norway, 1999–2008 – a retrospective study of hospital records to assess the sensitivity of surveillance. BMC Infectious Diseases. 2014;14(265):1-9.

Lingwood CA, Law H, Richardson. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. Journal of Biological Chemistry. 1987;262:8834–8839.

Obrig TG, Moran TP, Brown JE. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochemistry Journal. 1987;244:287–294.

Gourmelon M, Montet MP, Lozach S. Pathogenesis and diagnosis of shiga-toxin producing E. coli infections. Journal of Applied Microbiology. 2006;100(1):85-97.

Chong Y, Fitzhenry R, Heuschkel R, Torrente F, Frankel G, Phillips AD. Human intestinal tissue tropism in Escherichia coli O157: H7–initial colonization of terminal ileum and Peyer’s patches and minimal colonic adhesion ex vivo. Microbiology. 2007;153:794–802

Jerse AE, Gicquelais KG, Kaper JB. Plasmid and chromosomal elements involved in the pathogenesis of attaching and effacing Escherichia coli. Infection and Immunity. 1991;59:3869–3875.

Malyukova I, Murray KF, Zhu C. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2009;296:78–92.

Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. European Journal of Biochemistry. 1988;171:45–50.

Kendall MM, Sperandio V. Mechanisms and functions of interkingdom signaling in host-pathogen associations. MBio. 2016; 7:44-48.

Jacewicz MS, Acheson DW, Binion DG. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infection and Immunity. 1999;67:1439–1444.

Tazzari PL, Ricci F, Carnicelli D. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry part B Clinical Cytometry. 2004;61:40–44.

Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, Lethagen S. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001;97:3100–3108.

Stahl AL, Sartz L, Nelsson A, Bekassy ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. International Society of Nephrology. 2009;32:46-49.

Boineau FG, Corrigan JJ. Hemolytic-Uremic Syndrome. Pediatrics in Review. 2001;22:365-369.

Roessingh ASB, Lagausie P, Baudoin V, Loirat C, Aigrain Y. Gastrointestinal complications of postdiarrheal hemolytic uremic syndrome. European Journal of Pediatric Surgery. 2007;17(5):328–334.

Turi S, Nemeth I, Vargha I, Matkovics B. Oxidative damage of red blood cells in haemolytic uraemic syndrome. Pediatric Nephrology. 1994;8:26–29.

Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657–666.

Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR. Shiga toxin binds to activated platelets. Journal of Thrombrosis and Haemostasis. 2004;2: 499–506.

Guessous F, Marcinkiewicz M, Polanowska-Grabowska. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infection and Immunity. 2005;73(12):8306–8316.

Gear AR, Camerini D. Platelet chemokines and chemokine receptors: Linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10:335–350.

Lopez EL, Devoto S, Fayad A, Canepa C, Morrow AL, Cleary TG. Association between severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome. Journal of Pediatrics. 1992;120:210–215.

Boyer O, Niaudet P. Hemolytic uremic syndrome: New developments in pathogenesis and treatment. International Journal of Nephrology. 2011:1-10.

Dettmar AK, Binder E, Greiner FR. Protection of human podocytes from Shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component. Infection and Immunity. 2014; 82:1872–1879.

Karpman D, Hakansson A, Perez MT. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infection and Immunity. 1998;66:636–644.

Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxinproducing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: A prospective study. Journal of Infectious Diseases. 2002;186(4):493–500.

Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT. Predictors of fatality in postdiarrheal haemolytic uremic syndrome. Pediatrics. 2006;117(5):1656–1662.

Centres for Disease Control and Prevention. CDC Prevention Guidelines Database (Archive). E. coli 0157:H7: Procedure for Isolation and Identification from Stool Specimens. Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Micotic Diseases, National Centre for Infectious Diseases, Centres for Disease Control and Prevention MS C-091600 Clifton Rd Atlanta, GA 30333; 1994.

Frenzen PD, Drake A, Angulo FJ, The Emerging Infections Program Foodnet Working Group. Economic Cost of Illness Due to Escherichia coli O157 Infections in the United States. Journal of Food Protection. 2005;68(12):2623–2630.